Phase I study of ramucirumab, a recombinant human IgG1 monoclonal antibody inhibiting vascular endothelial growth factor receptor-2, in Chinese patients with advanced solid tumors

被引：0
|
作者：
Li, Jin
Cao, Junning
Wang, Jin
Li, Baoyue
Chi, Haidong
Gao, Ling
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-CT158
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT158
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Phase I study of every 2-or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors
    Chiorean, E. G.
    Hurwitz, H. I.
    Cohen, R. B.
    Schwartz, J. D.
    Dalal, R. P.
    Fox, F. E.
    Gao, L.
    Sweeney, C. J.
    ANNALS OF ONCOLOGY, 2015, 26 (06) : 1230 - 1237
  • [2] A phase I, pharmacological and biological study of weekly IMC-1121B, a recombinant human IgG1 monoclonal antibody (MAb), targeting vascular endothelial growth factor receptor 2 (VEGFR-2), in patients (pts) with advanced solid tumors
    Spratlin, Jennifer L.
    Eckhardt, S. Gail
    Gore, Lia
    Camidge, D. Ross
    Leong, Stephen
    O'Bryant, Cindy
    Diab, Sami
    Chow, Laura Q. M.
    Youssoufian, Hagop
    Fox, Floyd
    Cohen, Roger B.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3346S - 3346S
  • [3] Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors
    Lee, Su Jin
    Lee, Seon Young
    Lee, Weon Sup
    Yoo, Jin San
    Sun, Jong-Mu
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Ahn, Myung-Ju
    Lim, Ho Yeong
    Kang, Won Ki
    Park, Young Suk
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (06) : 782 - 790
  • [4] Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors
    Su Jin Lee
    Seon Young Lee
    Weon Sup Lee
    Jin San Yoo
    Jong-Mu Sun
    Jeeyun Lee
    Se Hoon Park
    Joon Oh Park
    Myung-Ju Ahn
    Ho Yeong Lim
    Won Ki Kang
    Young Suk Park
    Investigational New Drugs, 2017, 35 : 782 - 790
  • [5] A phase I study of IMC-11F8, a recombinant human anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors.
    Kuenen, Bart
    Witteveen, Petronella Oda
    Ruijter, Rita
    Tjin-A-Ton, Manuel
    Youssoufian, Hagop
    Rowinsky, Eric
    Fox, Floyd
    Wang, Guojun
    Giaccone, Giuseppe
    Emile, Voest
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3448S - 3449S
  • [6] A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors
    Higano, C. S.
    Yu, E. Y.
    Whiting, S. H.
    Gordon, M. S.
    LoRusso, P.
    Fox, F.
    Katz, T. L.
    Roecker, J. M.
    Schwartz, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in Japanese patients with solid tumors
    Boku, N.
    Yamazaki, K.
    Fukutomi, A.
    Takahashi, T.
    Yamamoto, N.
    Miyazaki, M.
    Satoh, T.
    Okamoto, I.
    Nakagawa, K.
    Fukuoka, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 134 - 134
  • [8] Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors in Japan
    Boku, N.
    Yamazaki, K.
    Yamamoto, N.
    Takahashi, T.
    Fukutomi, A.
    Miyazaki, M.
    Satoh, T.
    Okamoto, I.
    Nakagawa, K.
    Fukuoka, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Ramucirumab (IMC-1121B): Monoclonal Antibody Inhibition of Vascular Endothelial Growth Factor Receptor-2
    Jennifer Spratlin
    Current Oncology Reports, 2011, 13 : 97 - 102
  • [10] Ramucirumab (IMC-1121B): Monoclonal Antibody Inhibition of Vascular Endothelial Growth Factor Receptor-2
    Spratlin, Jennifer
    CURRENT ONCOLOGY REPORTS, 2011, 13 (02) : 97 - 102
12345